Tatton Consulting supported Oxford-based T-cell receptor discovery company Exogene in its successful application to UK – Germany Bilateral: Collaborative R&D, which was awarded £351,725 by Innovate UK for the project SpeedTCR – Unlocking the discovery of TCRs for HLA-peptide based and other precision cancer therapies.
About the funded R&D project
A UK-Germany collaborative project focused on accelerating the discovery of T-cell receptors for HLA-peptide based precision cancer therapies. Discovery speed is a direct commercial constraint in this field: the time taken to identify a viable receptor determines development cost and how quickly a therapy can reach patients.
Award details
- Grant awarded: £351,725
- Competition: UK – Germany Bilateral: Collaborative R&D
- Competition year: 2023/24
- Project: SpeedTCR – Unlocking the discovery of TCRs for HLA-peptide based and other precision cancer therapies
- Sector: Oncology / biotechnology
- UKRI project record: Gateway to Research, project 10080642
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title above are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
